Evidence map›Paper›PMID 35860649›Full record

ArticleCanadian journal of kidney health and disease2022

Determining Factors Influencing RAS Inhibitors Re-Initiation in ICU: A Modified Delphi Method.

Hadjer Dahel, Jean-Philippe Lafrance, Mathilde Patenaude, Kelley Kilpatrick, William Beaubien-Souligny, Mathieu Moreau, Han Ting Wang

Abstract read
In one paragraph

Article in Canadian journal of kidney health and disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hadjer DahelFaculty of Pharmacy, Université de Montréal, QC, Canada.ORCID https://orcid.org/0000-0001-8266-8378
Jean-Philippe LafranceDepartment of Pharmacology and Physiology, Faculty of Medicine, Université de Montréal, QC, Canada.
Mathilde PatenaudeDepartment of Medicine, Hôpital Maisonneuve-Rosemont, Affiliated with Université de Montréal, QC, Canada.
Kelley KilpatrickIngram School of Nursing, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
William Beaubien-SoulignyCentre hospitalier de l'Université de Montréal Research Center, QC, Canada.ORCID https://orcid.org/0000-0003-3030-8703
Mathieu MoreauCentre intégré universitaire de santé et de services sociaux du Nord-de-l'Île-de-Montréal, QC, Canada.
Han Ting WangCentre hospitalier de l'Université de Montréal Research Center, QC, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Renin-angiotensin system inhibitors (RASi) are not re-initiated for almost a quarter of patients who suffered acute kidney injury 6 months after discharge. This discontinuation might be partly explained by the nephrotoxicity of these medications, yet they remain of benefit, especially for patients with heart failure. Objective: To determine the factors deemed by clinicians to influence RASi re-initiation and set threshold values for important safety parameters. Design: Three-round modified online Delphi survey. Setting: The study was conducted in Quebec, Canada. Participants: Twenty clinicians from nephrology, intensive care medicine, and internal medicine. Measurements: The factors' importance was rated on 4-point Likert-type scale, ranging from "not important" to "very important" by the panelists. Methods: We conducted a brief literature review to uncover possible influencing factors followed by a 3-round modified Delphi survey to establish a consensus on the importance of these factors. Results: We recruited 20 clinicians (7 nephrologists, 3 internists, and 10 intensive care physicians). We created a list of 25 factors, 15 of which met consensus. Eleven of these factors, including serum creatinine, glomerular filtration rate, and acute kidney injury (AKI) stage, were deemed as important while 4, such as responsibility ambiguity and absence of feedback, were deemed as not important. The majority of the 10 factors which did not meet consensus were related to the clinical setting, such as a pharmacist follow-up and the required time to ensure optimal RASi re-initiation. Limitations: Quebec clinicians' agreement might not reflect the opinion of the rest of Canada. The survey measures clinicians' belief rather than their actual practice. Conclusion: Renin-angiotensin system inhibitors re-initiation is a rather complex concept which encompasses several factors. Our research uncovered some of these factors which may be used to develop guidelines on optimal RASi re-initiation.

Indexed as

acute kidney injuryintensive caremedication discontinuationmedication reconciliationrenin-angiotensin system inhibitors

Identifiers

PMID35860649
PMCPMC9290153

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.